NO20064237L - Furosemide modulatorer for HM74 - Google Patents

Furosemide modulatorer for HM74

Info

Publication number
NO20064237L
NO20064237L NO20064237A NO20064237A NO20064237L NO 20064237 L NO20064237 L NO 20064237L NO 20064237 A NO20064237 A NO 20064237A NO 20064237 A NO20064237 A NO 20064237A NO 20064237 L NO20064237 L NO 20064237L
Authority
NO
Norway
Prior art keywords
furosemide
modulators
molecules
prepare
host cells
Prior art date
Application number
NO20064237A
Other languages
English (en)
Norwegian (no)
Inventor
Hans-Jochen Lang
Haifeng Eishingdrelo
Anne Minnich
Theresa Kuntzweiler
Michael Angelastro
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20064237L publication Critical patent/NO20064237L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20064237A 2004-02-20 2006-09-19 Furosemide modulatorer for HM74 NO20064237L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20
PCT/US2005/004108 WO2005082350A1 (fr) 2004-02-20 2005-02-10 Derives de furosemides utilises comme modulateurs du hm74 et leur utilisation dans le traitement de l'inflammation

Publications (1)

Publication Number Publication Date
NO20064237L true NO20064237L (no) 2006-09-19

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064237A NO20064237L (no) 2004-02-20 2006-09-19 Furosemide modulatorer for HM74

Country Status (24)

Country Link
US (2) US7232811B2 (fr)
EP (1) EP1718292A1 (fr)
JP (1) JP2007523166A (fr)
KR (1) KR20060127141A (fr)
CN (1) CN1921845A (fr)
AR (1) AR047747A1 (fr)
AU (1) AU2005216879B2 (fr)
BR (1) BRPI0506792A (fr)
CA (1) CA2557444A1 (fr)
CR (1) CR8528A (fr)
EC (1) ECSP066777A (fr)
IL (1) IL177086A (fr)
MA (1) MA28373A1 (fr)
ME (1) MEP21108A (fr)
MX (1) MXPA06008612A (fr)
NO (1) NO20064237L (fr)
NZ (1) NZ548830A (fr)
RS (1) RS20060473A (fr)
RU (1) RU2006133540A (fr)
SG (1) SG164305A1 (fr)
TN (1) TNSN06234A1 (fr)
TW (1) TW200538109A (fr)
WO (1) WO2005082350A1 (fr)
ZA (1) ZA200606679B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
EP1603585A2 (fr) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
CA2635261A1 (fr) * 2006-01-03 2007-07-12 Algebra, Inc. Composes therapeutiques amine-arylsulfonamide conjugues
KR20080097426A (ko) * 2006-01-18 2008-11-05 쉐링 코포레이션 칸나비노이드 수용체 조절제
WO2008052190A2 (fr) * 2006-10-26 2008-05-02 Flynn Gary A Modulateurs d'aquaporine et procédés pour leur utilisation pour le traitement d'un oedème et d'un déséquilibre de fluides
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CA2692268A1 (fr) * 2007-06-28 2009-01-08 Intervet International B.V. Piperazines a substitution servant d'antagonistes des recepteurs cb1
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875150A (en) 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
DE2206424A1 (de) * 1971-02-15 1972-08-24 Dumex Ltd As Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
EP1007563A4 (fr) * 1997-06-12 2003-04-16 Smithkline Beecham Corp Recepteur hm74a
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
BRPI0506792A (pt) 2007-05-22
WO2005082350A8 (fr) 2005-12-08
ECSP066777A (es) 2006-11-16
SG164305A1 (en) 2010-09-29
IL177086A (en) 2010-06-16
IL177086A0 (en) 2006-12-10
MXPA06008612A (es) 2007-01-25
US20070213391A1 (en) 2007-09-13
AU2005216879A1 (en) 2005-09-09
ZA200606679B (en) 2008-01-30
US7556931B2 (en) 2009-07-07
CR8528A (es) 2007-06-08
AU2005216879B2 (en) 2009-12-10
NZ548830A (en) 2010-03-26
RU2006133540A (ru) 2008-03-27
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
JP2007523166A (ja) 2007-08-16
US7232811B2 (en) 2007-06-19
TNSN06234A1 (en) 2007-12-03
RS20060473A (en) 2008-08-07
TW200538109A (en) 2005-12-01
CN1921845A (zh) 2007-02-28
MEP21108A (en) 2010-06-10
CA2557444A1 (fr) 2005-09-09
EP1718292A1 (fr) 2006-11-08
AR047747A1 (es) 2006-02-15
MA28373A1 (fr) 2006-12-01
WO2005082350A1 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
NO20064237L (no) Furosemide modulatorer for HM74
AR073304A1 (es) Moduladores del receptor de bradiquinina b2 de molecula pequena
DE602005003446D1 (de) Blade Computer mit Notstromversorgung mittels Kondensatoren
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
DK2150530T3 (da) Substituerede sulfonamid-derivater
ECSP10010347A (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
NO20081034L (no) Pyrimidinforbindelser som serotoninreseptormodulatorer
MX2010003224A (es) Derivados de biaril sulfonamida.
DE602006009789D1 (de) Acetylenderivate
UA106880C2 (uk) Нові гербіциди
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
NO20080705L (no) Aminoaryl Sulphonamide Derivatives as functional 5-HT6 Ligands
BRPI0508471A (pt) hidróxi-6-fenilfenantridinas substituìdas por difluoroetóxi
NO20064214L (no) Oxydecahydronaphthalen-modulatorer for HM74
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EA201101097A1 (ru) Новые микробиоциды
MX2010006636A (es) Uso de derivados de acido tetramico para controlar nematodos.
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
NO20072071L (no) Flytende modulkonstruksjon
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
BRPI0907052B8 (pt) processo para a preparação de compostos
DK1963249T3 (da) Biphenylderivater som selektive agonister af gamma-RAR-receptorer
DE502008002979D1 (de) Arylsulfonamide mit analgetischer wirkung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application